Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN A TOENJES

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1679585764
CMS profile
212229
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$98,818.16

314 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 4 of 7; records 151–200 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN A TOENJES

NPI 1679585764 · CMS profile ID 212229

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 7; records 151–200 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679585764?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN A TOENJES, NPI 1679585764, CMS profile ID 212229. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679585764?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). STEVEN A TOENJES, NPI 1679585764, CMS profile ID 212229. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679585764?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
STEVEN A TOENJES, NPI 1679585764, CMS profile ID 212229, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 7; records 151–200 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1679585764?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

314 matching records · $98,818.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 314 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 314.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $82.8807/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796159737 CMS
Allergan, Inc. $3.3307/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792968209 CMS
UPSHER-SMITH LABORATORIES LLC $23.9507/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834691963 CMS
AbbVie Inc. $11.2307/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796159733 CMS
Allergan, Inc. $20.0607/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792968207 CMS
AbbVie Inc. $3.3707/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796159731 CMS
AbbVie Inc. $3.4106/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796159729 CMS
Allergan, Inc. $8.5106/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792968205 CMS
Amgen Inc. $2,850.0006/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825804849 CMS
AbbVie Inc. $4.1506/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796159725 CMS
AbbVie Inc. $4.3806/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796159727 CMS
EMD Serono, Inc. $29.9506/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849198883 CMS
Amgen Inc. $17.2206/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825804853 CMS
Lilly USA, LLC $750.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818737123 CMS
Novartis Pharmaceuticals Corporation $14.4206/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813316615 CMS
AbbVie Inc. $4.5706/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796159721 CMS
AbbVie Inc. $7.7506/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796159723 CMS
Allergan, Inc. $10.0806/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792968203 CMS
Biohaven Pharmaceuticals, Inc. $25.1406/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852642839 CMS
Amgen Inc. $12.6106/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825804833 CMS
Celgene Corporation $1.7506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783684989 CMS
GENZYME CORPORATION $21.6506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843549597 CMS
Janssen Pharmaceuticals, Inc $17.3606/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788554331 CMS
Allergan, Inc. $7.8506/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792968201 CMS
Amgen Inc. $25.0406/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825804829 CMS
JAZZ PHARMACEUTICALS INC. $121.5206/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845607167 CMS
Supernus Pharmaceuticals, Inc. $16.8506/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845124717 CMS
Teva Pharmaceuticals USA, Inc. $0.8706/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839537365 CMS
Teva Pharmaceuticals USA, Inc. $17.9806/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839537367 CMS
ACADIA Pharmaceuticals Inc $18.8406/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838022887 CMS
AbbVie Inc. $1,920.0006/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796159717 CMS
AbbVie Inc. $17.8306/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796159719 CMS
Novartis Pharmaceuticals Corporation $21.7706/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813316559 CMS
Amgen Inc. $16.3606/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825804781 CMS
AbbVie Inc. $8.7505/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796159715 CMS
Allergan, Inc. $6.8405/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792968197 CMS
Allergan, Inc. $2.6305/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792968199 CMS
JAZZ PHARMACEUTICALS INC. $18.8205/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845592945 CMS
Biogen, Inc. $21.8405/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827859331 CMS
Celgene Corporation $124.9305/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783685005 CMS
Novartis Pharmaceuticals Corporation $21.8205/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813316611 CMS
Allergan, Inc. $13.8605/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792968195 CMS
Lilly USA, LLC $750.0005/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818753565 CMS
Eisai Inc. $17.4005/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817923691 CMS
Lilly USA, LLC $14.0805/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818703749 CMS
Sunovion Pharmaceuticals Inc. $27.0605/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821523827 CMS
Novartis Pharmaceuticals Corporation $24.9105/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813316607 CMS
Lilly USA, LLC $750.0005/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818703755 CMS
Novartis Pharmaceuticals Corporation $4.9505/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813316603 CMS
UPSHER-SMITH LABORATORIES LLC $24.7005/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834683281 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $101,818.22 235
PY2020 $136,232.37 270
PY2021 $98,818.16 314
PY2022 $88,348.43 244
PY2023 $48,241.43 245
PY2024 $104,996.78 276
PY2025 $116,211.61 223

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $952,343.17 31
PY2024 Principal investigator $1,278,888.09 10
PY2023 Recipient $3,268.99 3
PY2023 Principal investigator $2,130,424.04 15
PY2022 Recipient $3,075.00 2
PY2022 Principal investigator $1,152,383.00 8
PY2021 Recipient $10,126.59 2
PY2021 Principal investigator $561,074.11 17
PY2020 Principal investigator $53,127.07 53
PY2019 Principal investigator $71,597.00 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,303.40 12/27/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228736543
Principal investigator 1 PFIZER INC. $123.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228745673
Principal investigator 1 PFIZER INC. $2,917.60 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228736663
Principal investigator 1 Merz Pharmaceuticals, LLC $2,000.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647334
Principal investigator 1 Merz Pharmaceuticals, LLC $1,750.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647336
Principal investigator 1 Merz Pharmaceuticals, LLC $19,000.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647338
Principal investigator 1 Merz Pharmaceuticals, LLC $19,000.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647340
Principal investigator 1 Merz Pharmaceuticals, LLC $1,750.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647342
Principal investigator 1 Merz Pharmaceuticals, LLC $250.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647344
Principal investigator 1 Merz Pharmaceuticals, LLC $250.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647346
Principal investigator 1 Merz Pharmaceuticals, LLC $2,000.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647348
Principal investigator 1 PFIZER INC. $1,328.00 11/07/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228728051
Principal investigator 1 PFIZER INC. $2,869.68 11/04/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228738617
Principal investigator 1 PFIZER INC. $1,376.20 11/01/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228726995
Principal investigator 1 PFIZER INC. $3,082.80 10/21/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228741661
Principal investigator 1 PFIZER INC. $6,980.40 09/09/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228761503
Principal investigator 1 PFIZER INC. $50.40 08/29/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228767996
Principal investigator 1 PFIZER INC. $4,849.70 08/05/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228751373
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,622.64 07/28/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235996507
Principal investigator 1 PFIZER INC. $5,657.40 07/25/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228764656
Principal investigator 1 PFIZER INC. $6,256.96 07/18/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228763875
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $42,600.53 07/14/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235996505
Principal investigator 1 PFIZER INC. $17,250.00 07/02/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228765241
Principal investigator 1 Eli Lilly and Company $6.72 05/16/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187881638
Principal investigator 1 Eli Lilly and Company $903.50 04/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187886012
Principal investigator 1 Eli Lilly and Company $310,793.00 02/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187884776
Principal investigator 1 Eli Lilly and Company $8,559.29 02/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885372
Principal investigator 1 Eli Lilly and Company $895.75 01/27/2025 Non-covered Recipient Entity
ENCORE BORLAND-GROOVER CLINICAL
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883332
Principal investigator 1 Eli Lilly and Company $80,752.00 01/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187881006
Principal investigator 1 Eli Lilly and Company $301,928.00 01/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187885010
Principal investigator 1 Eli Lilly and Company $104,236.00 01/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187885214